Overall, it can be assumed that the onco-promoter/onco-suppressor role of Nrf2 varies by melanoma stage, and whereas transient Nrf2 activity protects against tumor development, constitutive Nrf2 activation may encourage cancer progression and metastasis. Here, NFE2L2 is linked to cancer.